Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma
Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma
复制标题
DOI：
10.1097/cmr.0b013e3283550aa5
复制
发表时间：
2012-08-01
影响因子：
2.2
通讯作者：
Schmidt, Henrik
中科院分区：
文献类型：
--
作者：
Hoejberg, Lise;Bastholt, Lars;Schmidt, Henrik
白细胞介素-6 （IL-6）是一种由正常细胞和肿瘤细胞（包括黑色素瘤细胞）产生的免疫调节细胞因子。IL-6在黑色素瘤中的具体生物学功能尚不清楚。本研究探讨血清IL-6浓度是否可以预测转移性黑色素瘤患者的预后。采用ELISA法检测103例转移性黑色素瘤患者在il -2免疫治疗前的血清样本中的IL-6。转移性黑色素瘤患者血清IL-6高于健康个体(中位值3.4 ng/l，范围0.3-93 ng/l vs中位值1.4 ng/l，范围0.25-22.5 ng/l， P
Interleukin-6 (IL-6) is an immunomodulatory cytokine produced by both normal cells and tumor cells, including melanoma cells. The specific biological function of IL-6 in melanoma is unknown. The present study examined whether the serum concentration of IL-6 can predict prognosis in patients with metastatic melanoma. IL-6 was measured by ELISA in serum samples from 103 patients with metastatic melanoma obtained before IL-2-based immunotherapy. Patients with metastatic melanoma had higher serum IL-6 than healthy individuals (median 3.4 ng/l, range 0.3-93 ng/l vs. median 1.4 ng/l, range 0.25-22.5 ng/l, P